Peter J. Kushner, Ph.D.
Peter is the founding Chairman and CSO of Olema. He is an Emeritus Professor in the Department of Medicine, Division of Endocrinology, University of California, San Francisco. He has studied the mechanisms and functions of the estrogen receptors and has published some of the most highly cited papers in the field, including ones showing the molecular mechanism of action of the breast cancer drug tamoxifen. Along with other colleagues from UCSF he was a founder of Serra Pharmaceuticals, a California biotechnology company which was purchased by KaroBio AB, in Stockholm, Sweden. He served on the Board of Directors of KaroBio from 1996 to 2002.
Cyrus L. Harmon, Ph.D.
Cyrus is the founding CEO and President of Olema. He was the co-founder and CEO of Neomorphic, Inc., a computational biology company that was acquired by Affymetrix, Inc., where he served as Vice President, Computational Genomics and General Manager. He received a Ph.D. in Molecular and Cell Biology from UC Berkeley, where he applied computer vision and machine learning techniques to the analysis of spatial patterns of gene expression in Drosophila melanogaster.
Andrei Manoliu, Ph.D., J.D.
Andrei is the founder of GrowthPlans, which provides business and financial advice to emerging growth companies. Prior to founding GrowthPlans, he practiced law for almost 20 years with the leading Silicon Valley firm of Cooley LLP. Andrei serves on the board of several private companies.
Andrei holds a Ph. D. in Solid State Physics from the University of California, Berkeley, and a law degree from Stanford University, where he was elected to the Order of the Coif.
Peter is an acclaimed futurist and Senior Vice President for Strategic Planning at Salesforce. Prior to joining Salesforce, he was a cofounder and chairman of Global Business Network. He is a member of the Council on Foreign Relations, the World Affairs Council, and the Research, Innovation and Enterprise Council in Singapore. He sits on the boards of the Long Now Foundation and the Center for Strategic Futures in Singapore.
From 1982 to 1986, Peter headed scenario planning for the Royal Dutch/Shell Group of Companies in London, where his team conducted comprehensive analyses of the global business and political environment. Before joining Royal Dutch/Shell, he directed the Strategic Environment Center at SRI International.
Peter is the author of Inevitable Surprises (Gotham, 2003) and The Art of the Long View (Doubleday Currency, 1991). He is a co-author of The Long Boom (Perseus, 1999), When Good Companies Do Bad Things (Wiley, 1999) and China's Futures (Jossey-Bass, 2001). He has served as a script consultant on the films "The Minority Report," "Deep Impact," "Sneakers," and "War Games."
Peter received a B.S. in aeronautical engineering and astronautics from Rensselaer Polytechnic Institute (RPI) in New York, and in 2009 delivered the commencement address and received an honorary Ph.D. for contributions to management from RPI.
Marina is the Head of Biotech & Pharma, Managing Director, at William Blair & Company, which she joined in 2010. Seh has over 25 years of investment banking and other healthcare industry expertise, including raising more than $25 billion in capital and executing numerous M&A transactions. Most recently, she was a principal at Kidd & Company, a private-equity firm, and prior to that, worked at Bear, Stearns & Co. Inc. as a senior managing director in the healthcare group. Before that, Marina was was a Managing Director and Head of Biotechnology at Bank of America Securities, and a Partner at Vector Securities International.
Marina is a Director of NeuroNetworks Fund, a non-profit organization focused on therapies for autism, epilepsy, schizophrenia and related disorders, and serves on the Advisory Board of Arctic Aurora Life Sciences, a Swedish healthcare-focused investment fund.
Marina received her B.A. in molecular biology and M.A. in economic history from the University of Chicago.
Andy is Managing Partner of Skyline Public Works, Chief Investment Officer of SPW Investments, and Treasurer of the Rappaport Family Foundation. He has spent more than 30 years founding, investing in, and guiding scores of transformative start-up companies. From 1996 until his retirement in 2012, Andy was a partner at August Capital, a leading technology venture capital firm, which he helped grow from $100M to more than $2B under management. Prior to joining August, Andy ran The Technology Research Group, a Boston-based global strategy consulting firm he founded in 1984.
Andy is a noted authority on the business and economic implications of changing technologies, and has written and spoken extensively on the topic. Technology companies Andy co-founded, led investments in, and/or served as a board member of include Actel, Atheros Communications, MMC Networks, Silicon Architects, Silicon Image, and Transmeta. With his wife, Deborah, Andy is also founder of the Minnesota Street Project, a collection of buildings in San Francisco’s Dogpatch Neighborhood that provide below-market rents to artist, art galleries, and arts-related non-profits, as well as related public programming and services.
Frank McCormick, Ph.D., FRS, D.Sc (Hon)
Frank is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Frank pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. In addition, Frank’s group led to the identification of the CDK4 kinase inhibitor, Palbociclib, approved for treating advanced breast cancer. Frank's current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies.
Frank holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. He is the author of over 320 scientific publications and holds more than 20 issued patents. He was Director of the Helen Diller Family Comprehensive Cancer Center from 1997 to 2014. He also served as President, 2012-2013, for the American Association for Cancer Research (AACR). Since 2013 he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers.